Understand pulmonary fibrosis treatment options: A clinical overview of current care

Pulmonary fibrosis treatment options depend on whether the scarring is idiopathic, linked to an autoimmune disease or exposure, or part of another interstitial lung disease. Current care generally aims to slow progression, relieve breathlessness and cough, preserve daily function, prevent complications, and assess whether transplantation or research participation is appropriate. Lung scarring is usually permanent, and no consistently reliable treatment currently reverses it or guarantees that progression will stop. 1

How treatment is selected

Pulmonary fibrosis is a broad category rather than one single disease. Causes can include medications, immune diseases, inhaled toxins such as asbestos, and cases in which no trigger is identified. Idiopathic pulmonary fibrosis, or IPF, is the best-known form, while progressive pulmonary fibrosis can develop in other interstitial lung diseases. Because treatment differs by subtype, expert review and multidisciplinary assessment are important before disease-specific therapy is selected. 2

Assessment commonly includes a specialist diagnosis, high-resolution imaging, lung-function testing, and monitoring of change over time. Spirometry and forced vital capacity are among the measures used to evaluate lung function and treatment response. The TSANZ guideline summary recommends confirming IPF through a multidisciplinary meeting before antifibrotic treatment, reflecting the risk of treating the wrong disease category. 3

Antifibrotic medicines for IPF

Nintedanib and pirfenidone are the established antifibrotic medicines used to slow the decline of lung function in IPF. They do not remove existing scar tissue and are not described as cures, but clinical guidance supports their use in appropriate patients, including those with mild-to-moderate disease within the eligibility ranges specified by local regulators and health systems. Treatment decisions require individualized review of disease severity, other illnesses, liver health, and likely tolerability. 4

• Nintedanib may cause gastrointestinal effects, including diarrhea, and is managed clinically with measures such as taking doses with meals and, when appropriate, antidiarrheal treatment.
• Pirfenidone can cause photosensitivity, making strict sun protection an important part of ongoing use.
• Both medicines require attention to liver function, and both are contraindicated in severe hepatic impairment.
• Routine combination antifibrotic treatment is not recommended outside clinical trials, and disease progression alone is not evidence that switching agents will improve the disease trajectory. 2

Antifibrotic care for progressive disease

Progressive pulmonary fibrosis describes worsening fibrotic behavior in some non-IPF interstitial lung diseases. The underlying diagnosis remains important because autoimmune or other contributing conditions may need targeted treatment, while the observed pattern of progression can lead clinicians to consider antifibrotic therapy. Nintedanib has been incorporated into treatment discussions for selected patients with progressive disease, but eligibility and authorization rules vary by jurisdiction. 5

Progression is evaluated through symptoms, imaging, exercise tolerance, and serial pulmonary-function results rather than a single measurement. A multidisciplinary team may reassess the diagnostic classification as the disease evolves. This approach recognizes that patients with apparently similar scarring can have different causes, rates of decline, comorbidities, and responses to treatment. Medication monitoring is therefore ongoing, and treatment plans may change when adverse effects, liver abnormalities, or new clinical findings appear. 2

Oxygen and pulmonary rehabilitation

Supplemental oxygen is used when blood oxygen levels are inadequate, including during activity or rest when clinically indicated. Oxygen can help manage hypoxemia and improve tolerance for daily activities, but it does not reverse fibrosis. Prescribing decisions are based on measured oxygenation and functional needs, with equipment and usage patterns shaped by the individual’s clinical assessment. 6

• Pulmonary rehabilitation may include supervised exercise training, breathing techniques, education, and nutritional counseling.
• Rehabilitation is intended to improve exercise capacity, physical function, and quality of life rather than remove lung scars.
• Smoking cessation and avoidance of inhaled toxins, including air pollution where possible, are general health measures used in management.
• Vaccination against routine respiratory infections is emphasized because infections can add stress to already impaired lungs. 1

Managing symptoms and related conditions

Breathlessness and persistent cough can remain significant even when antifibrotic treatment is prescribed. Supportive care may include oxygen, cough-focused treatment, anxiety management, and palliative care. Palliative care is not limited to the final stage of illness: it can address symptoms, emotional strain, communication, and family support alongside disease-directed treatment. 1

Care also considers conditions that may worsen respiratory burden or complicate treatment, including gastroesophageal reflux disease and autoimmune illness. When an underlying disease such as lupus contributes to lung disease, effective treatment of that illness may slow further scarring. Decisions about reflux management and immunosuppressive treatment require diagnosis-specific medical judgment rather than a uniform plan for every person with fibrosis. 7

Transplantation, monitoring, and research

Lung transplantation is a potential definitive treatment for selected people with advanced pulmonary fibrosis who remain suitable candidates. Referral depends on factors such as disease severity, overall health, functional status, and transplant-center eligibility criteria. Transplantation also involves major evaluation, surgical risk, lifelong follow-up, and ongoing medical treatment, so it is considered within specialist care rather than as a routine option for all patients. 8

Clinical trials remain important because current antifibrotic medicines slow decline but do not reliably reverse established fibrosis. Research is examining new therapeutic targets, including autotaxin inhibitors, monoclonal antibodies, pathway-directed agents, inhaled treprostinil, and other emerging approaches. These treatments may be investigational, may have uncertain benefits and risks, and are subject to regulatory oversight and trial eligibility requirements. 9

Questions to review with a specialist

A useful treatment discussion should identify the precise fibrosis subtype, evidence of progression, current lung-function results, oxygen needs, and the purpose of each proposed intervention. Medication conversations should cover expected benefit, liver monitoring, gastrointestinal effects, photosensitivity, interactions, and circumstances requiring reassessment. Patients may also ask how pulmonary rehabilitation, vaccination, smoking cessation, reflux care, symptom support, and psychosocial services fit into the overall plan. 2

Prognosis varies substantially by cause, disease behavior, age, comorbidities, and response to care. IPF is a serious, potentially life-threatening condition, and a frequently cited median survival estimate of four to five years after diagnosis comes from an educational pharmacy review, but an individual outcome cannot be predicted from that figure alone. Specialist monitoring helps identify progression, complications, transplant eligibility, and appropriate supportive-care needs. 10

Sources

1. Harvard Health, Pulmonary Fibrosis
2. Medscape, IPF and PPF Treatment: TSANZ 2024 Guideline Summary
3. NCBI Bookshelf, Interstitial Lung Disease
4. Pulmonology Advisor, Pulmonary Fibrosis Treatment Information
5. Medicina, Holistic Management of Pulmonary Fibrosis
6. Mayo Clinic, Pulmonary Fibrosis Diagnosis and Treatment
7. Pulse Today, Key Questions on Pulmonary Fibrosis and Interstitial Lung Disease
8. Cleveland Clinic, Pulmonary Fibrosis
9. Pulmonary Fibrosis Foundation, Types of Pulmonary Fibrosis
10. U.S. Pharmacist, Optimizing Idiopathic Pulmonary Fibrosis Management